Literature DB >> 32635641

Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals.

Estela Dámaso1, Maribel González-Acosta1,2, Gardenia Vargas-Parra1,2, Matilde Navarro1,2, Judith Balmaña3, Teresa Ramon Y Cajal4, Noemí Tuset5, Bryony A Thompson6, Fátima Marín1,2, Anna Fernández1, Carolina Gómez1, Àngela Velasco2,7, Ares Solanes1, Sílvia Iglesias1,2, Gisela Urgel5, Consol López4, Jesús Del Valle1,2, Olga Campos1, Maria Santacana8, Xavier Matias-Guiu2,8,9, Conxi Lázaro1,2, Laura Valle1,2, Joan Brunet1,2,7,10, Marta Pineda1,2, Gabriel Capellá1,2.   

Abstract

The causal mechanism for cancer predisposition in Lynch-like syndrome (LLS) remains unknown. Our aim was to elucidate the constitutional basis of mismatch repair (MMR) deficiency in LLS patients throughout a comprehensive (epi)genetic analysis. One hundred and fifteen LLS patients harboring MMR-deficient tumors and no germline MMR mutations were included. Mutational analysis of 26 colorectal cancer (CRC)-associated genes was performed. Pathogenicity of MMR variants was assessed by splicing and multifactorial likelihood analyses. Genome-wide methylome analysis was performed by the Infinium Human Methylation 450K Bead Chip. The multigene panel analysis revealed the presence of two MMR gene truncating mutations not previously found. Of a total of 15 additional MMR variants identified, five -present in 6 unrelated individuals- were reclassified as pathogenic. In addition, 13 predicted deleterious variants in other CRC-predisposing genes were found in 12 probands. Methylome analysis detected one constitutional MLH1 epimutation, but no additional differentially methylated regions were identified in LLS compared to LS patients or cancer-free individuals. In conclusion, the use of an ad-hoc designed gene panel combined with pathogenicity assessment of variants allowed the identification of deleterious MMR mutations as well as new LLS candidate causal genes. Constitutional epimutations in non-LS-associated genes are not responsible for LLS.

Entities:  

Keywords:  Lynch syndrome; Lynch-like syndrome; cancer genes panel; epimutation; methylation; mismatch repair; next generation sequencing; variant of unknown significance

Year:  2020        PMID: 32635641     DOI: 10.3390/cancers12071799

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

Review 1.  How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies.

Authors:  Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

Review 2.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

3.  Pseudotime Analysis Reveals Exponential Trends in DNA Methylation Aging with Mortality Associated Timescales.

Authors:  Kalsuda Lapborisuth; Colin Farrell; Matteo Pellegrini
Journal:  Cells       Date:  2022-02-22       Impact factor: 6.600

4.  A Previously Unrecognized Molecular Landscape of Lynch Syndrome in the Mexican Population.

Authors:  Alejandra Padua-Bracho; José A Velázquez-Aragón; Verónica Fragoso-Ontiveros; Paulina María Nuñez-Martínez; María de la Luz Mejía Aguayo; Yuliana Sánchez-Contreras; Miguel Angel Ramirez-Otero; Marcela Angélica De la Fuente-Hernández; Silvia Vidal-Millán; Talia Wegman-Ostrosky; Abraham Pedroza-Torres; Cristian Arriaga-Canon; Luis A Herrera-Montalvo; Rosa Maria Alvarez-Gómez
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.